Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 10/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.34 |
| ▸ | PIK3R2 | O00459 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
| ▸ | DHODH | Q02127 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4240859 | 0.89 | CRBN (0.32) | KDM4EALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL4242508 | 0.88 | CRBN (0.32) | — | |
| SCHEMBL4239785 | 0.87 | ALDH1A1 (0.35) | KDM4EALDH1A1LMNA | |
| SCHEMBL4241487 | 0.87 | KMT2A (0.35) | KDM4ELMNA | |
| SCHEMBL4235958 | 0.86 | CHIA (0.32) | KDM4E | |
| SCHEMBL4239588 | 0.85 | SPR (0.32) | — | |
| SCHEMBL4235967 | 0.85 | RORC (0.38) | KDM4EALDH1A1LMNA | |
| SCHEMBL4241846 | 0.85 | HCN1 (0.30) | — | |
| Malonic Acid SCHEMBL4248717 | 0.85 | CRBN (0.30) | — | |
| SCHEMBL4239937 | 0.85 | CDK2 (0.34) | KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093473-A1 | Spiro-benzimidazoles as inhibitors of gastric acid secretion | NYCOMED GMBH (DE) | 2009-04-09 | — | — | US | claimed |
| EP-1899338-A1 | SPIRO-BENZIMIDAZOLES AS INHIBITORS OF GASTRIC ACID SECRETION | Nycomed GmbH (DE) | 2008-03-19 | — | — | EP | claimed |
| WO-2006134111-A1 | SPIRO-BENZIMIDAZOLES AS INHIBITORS OF GASTRIC ACID SECRETION | NYCOMED GMBH (DE) | 2006-12-21 | — | — | WO | claimed |
| US-20090093473-A1 | Spiro-benzimidazoles as inhibitors of gastric acid secretion | NYCOMED GMBH (DE) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093473-A1 | Spiro-benzimidazoles as inhibitors of gastric acid secretion | GIPR, PGC, SLC10A2 | PARP1 4813/4885PARP2 4787/4885PIK3R2 3578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.